ATE388399T1 - Verwendung von hroralpha rezeptoren zur auffindung von anti-atherosclerotischen verbindungen - Google Patents

Verwendung von hroralpha rezeptoren zur auffindung von anti-atherosclerotischen verbindungen

Info

Publication number
ATE388399T1
ATE388399T1 AT99916886T AT99916886T ATE388399T1 AT E388399 T1 ATE388399 T1 AT E388399T1 AT 99916886 T AT99916886 T AT 99916886T AT 99916886 T AT99916886 T AT 99916886T AT E388399 T1 ATE388399 T1 AT E388399T1
Authority
AT
Austria
Prior art keywords
receptors
hroralpha
substances
screening
find anti
Prior art date
Application number
AT99916886T
Other languages
English (en)
Inventor
Eric Raspe
Yves Bonhomme
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Application granted granted Critical
Publication of ATE388399T1 publication Critical patent/ATE388399T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70567—Nuclear receptors, e.g. retinoic acid receptor [RAR], RXR, nuclear orphan receptors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Veterinary Medicine (AREA)
  • Vascular Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Plant Substances (AREA)
AT99916886T 1998-03-20 1999-03-24 Verwendung von hroralpha rezeptoren zur auffindung von anti-atherosclerotischen verbindungen ATE388399T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9803475A FR2776388B1 (fr) 1998-03-20 1998-03-20 Utilisation de recepteurs de la famille ror pour le criblage de substances utiles pour le traitement de l'atherosclerose

Publications (1)

Publication Number Publication Date
ATE388399T1 true ATE388399T1 (de) 2008-03-15

Family

ID=9524312

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99916886T ATE388399T1 (de) 1998-03-20 1999-03-24 Verwendung von hroralpha rezeptoren zur auffindung von anti-atherosclerotischen verbindungen

Country Status (13)

Country Link
US (1) US6998254B1 (de)
EP (1) EP1070253B1 (de)
JP (1) JP4520039B2 (de)
AT (1) ATE388399T1 (de)
AU (1) AU752062B2 (de)
CA (1) CA2326141C (de)
DE (1) DE69938297T2 (de)
DK (1) DK1070253T3 (de)
ES (1) ES2303374T3 (de)
FR (1) FR2776388B1 (de)
NZ (1) NZ507761A (de)
PT (1) PT1070253E (de)
WO (1) WO1999050660A1 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9924057D0 (en) * 1999-10-11 1999-12-15 Novartis Ag Organic compounds
MXPA02008616A (es) * 2000-03-03 2003-02-24 Smithkline Beecham Biolog Vacuna para el tratamiento de la arterosclerosis.
FR2813315B1 (fr) 2000-08-23 2002-10-18 Genfit S A Procede d'identification de substances utiles pour le traitement de l'inflammation mettant en oeuvre l'element de reponse du recepteur ror du gene ikbalpha
WO2003000732A2 (en) * 2001-05-07 2003-01-03 Centre National De La Recherche Scientifique Fragments of the retinoic acid-related orphan receptor (ror) comprising the lig and binding domain (lbd), crystal structure of the lbd of ror-beta and their applications
AU2003227689A1 (en) * 2002-04-29 2003-11-17 Novartis Ag Crystal structure of the ligand binding domain of the retinoic acid-related orphan receptor alpha (ror-alpha)
GB0306185D0 (en) * 2003-03-19 2003-04-23 Astrazeneca Ab Molecules
US9290476B2 (en) 2012-10-16 2016-03-22 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of RORγt
CN105073729A (zh) 2012-10-16 2015-11-18 詹森药业有限公司 RORγt的苯基连接的喹啉基调节剂
CN104884448A (zh) 2012-10-16 2015-09-02 詹森药业有限公司 Rorγt的杂芳基连接的喹啉基调节剂
US10555941B2 (en) 2013-10-15 2020-02-11 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of RORγt
US9403816B2 (en) 2013-10-15 2016-08-02 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of RORγt
US9328095B2 (en) 2013-10-15 2016-05-03 Janssen Pharmaceutica Nv Heteroaryl linked quinolinyl modulators of RORgammat
US9221804B2 (en) 2013-10-15 2015-12-29 Janssen Pharmaceutica Nv Secondary alcohol quinolinyl modulators of RORγt
BR112016008258A2 (pt) 2013-10-15 2017-10-10 Janssen Pharmaceutica Nv moduladores de ror?t de quinolinila
BR112016008215A2 (pt) 2013-10-15 2017-09-26 Janssen Pharmaceutica Nv moduladores de quinolinila ligados por alquila de roryt
JP6391687B2 (ja) * 2013-10-15 2018-09-19 ヤンセン ファーマシューティカ エヌ．ベー． Ｒｏｒγｔのヘテロアリール結合キノリニルモジュレーター
US9284308B2 (en) 2013-10-15 2016-03-15 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of RORγt
CN111088369B (zh) * 2020-01-17 2022-11-15 天津奥群牧业有限公司 一种绵羊rora基因插入/缺失多态性的检测方法、引物对和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5721096A (en) * 1991-01-24 1998-02-24 Children's Medical Center Corporation Methods of screening for compounds with ability to alter apolipoprotein AI gene expression
AU2109695A (en) * 1994-03-30 1995-10-23 Novartis Ag Screening method using the rzr receptor family
EP0693513B1 (de) * 1994-07-18 2001-01-10 Asahi Glass Company Ltd. Verfahren zur Polyetherreinigung
US5834248A (en) * 1995-02-10 1998-11-10 Millennium Pharmaceuticals Inc. Compositions and methods using rchd534, a gene uregulated by shear stress

Also Published As

Publication number Publication date
AU752062B2 (en) 2002-09-05
US6998254B1 (en) 2006-02-14
FR2776388B1 (fr) 2006-04-28
NZ507761A (en) 2002-10-25
CA2326141C (en) 2011-04-26
FR2776388A1 (fr) 1999-09-24
JP4520039B2 (ja) 2010-08-04
AU3521599A (en) 1999-10-18
CA2326141A1 (en) 1999-10-07
DK1070253T3 (da) 2008-06-23
DE69938297D1 (de) 2008-04-17
PT1070253E (pt) 2008-06-17
EP1070253B1 (de) 2008-03-05
EP1070253A1 (de) 2001-01-24
WO1999050660A1 (en) 1999-10-07
JP2004500539A (ja) 2004-01-08
ES2303374T3 (es) 2008-08-01
DE69938297T2 (de) 2009-03-19

Similar Documents

Publication Publication Date Title
ATE388399T1 (de) Verwendung von hroralpha rezeptoren zur auffindung von anti-atherosclerotischen verbindungen
DE60038035D1 (de) Headerkomprimierung durch verwendung von divisionsresten
DE69836332D1 (de) Benzyliden-1,3-dihydro-indol-2-on-derivate als inhibitoren von rezeptor tyrosine kinasesn, insbesondere von raf kinasen
DE69628484D1 (de) Zyklische Verbindungen, ihre Herstellung und ihre Verwendung als Tachykininrezeptorantagonisten
AR008919A1 (es) Anticuerpos anti-cd11a humanizados.
ATE193553T1 (de) Domänen von extrazellulären bereichen von menschlichen blutplättchen abstammenden wachstumsfaktor rezeptor-polypeptiden
TR199801255T2 (xx) Vitronektin resept�r antagonistleri.
DE59102431D1 (de) Ungesättigte Phenonderivate und ihre Verwendung als Haftklebstoffe.
DE60239552D1 (de) Messung der protein-syntheseraten bei menschen und in experimentellen systemen durch verwendung von isotopisch markiertem wasser
DK0951551T3 (da) Ligand for NF-kappa B-receptoraktivator, ligand er medlem af TNF-superfamilien
ATE508363T1 (de) Verfahren zur herstellung eines bioanalytischen reagenzes, nachweisverfahren beruhend auf der verwendung des bioanalytischen reagenz, sowie dessen verwendung
NO20014131D0 (no) Epitoper eller mimotoper avledet fra C-epsilon-3- eller C- epsilon-4-domener fra IgE, antagonister derav og deresterapeutiske anvendelser
DE69719576D1 (de) Fluor-desoxy-glucose-Synthetisierer unter Verwendung von Kolonnen
DE69915725D1 (de) Datenkompression unter Verwendung von Primzahlexponenten
DE69128941D1 (de) Verwendung von angiotensin-ii-rezeptorantagonisten in der behandlung der diabetischen nephropathie
ATE553256T1 (de) Faserhaltigen substraten
ATE210163T1 (de) Triazinpolymere und deren verwendung in elektrolumineszierenden anordnungen
DE60207254D1 (de) Natürlicher ligand von gpcr chemr23 und dessen verwendung
DE69712578D1 (de) Verwendung mindestens eines in 6-Stellung substituierten Pyrimidin-3-oxids zur Stimulierung von Tyrosinase
DE69915113D1 (de) 5ht1 rezeptor antagonisten und ihre verwendung für die behandlung von depression
DE69633131D1 (de) Rezeptor des y-y5 neuropeptids
DE69615073D1 (de) Frühzeitige Erkennung des Kondensationsrisikos von Wasser
DE69125175D1 (de) Verwendung von angiotensin-ii-rezeptorantagonisten bei der behandlung von atheromen
TR199700547A2 (xx) N-asetonilbenzamid fungisitler.
ATE250630T1 (de) Kristalle von fragmenten von cd40-liganden und deren verwendung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1070253

Country of ref document: EP